Griffith University

BMed(Hons), FRACP, MD

Senior Lecturer

Contact details for Dr Peter Davoren

Biography    

Dr Peter Davoren is a Senior Staff Specialist Physician practising in general medicine, diabetes and endocrinology. His main research interests and experience are clinical research in type 2 diabetes. He has been the Principal Investigator in a number of large multi-centre trials in diabetes management and has also conducted research at a local level in diabetes management. Dr Davoren is the Director of Physician Training at the Gold Coast Hospital.

Research interest   

• Clinical research in adult diabetes mellitus

Current research projects    

• ADVANCE - international multicentre, investigator driven trials in diabetes
• DIRECT - international multicentre, investigator driven trials in diabetes
• Use of continuous blood glucose monitoring in type 2 diabetes

Current grant   

• "Treatment of gestational diabetes with metformin campared with insulin" - NHMRC 2003, $244,500.  Hague WM, Oats JN, Haslam RR, and Davoren PM

Publications

Refereed journal articles

• Burgess DC, Hunt D, Li L, Zannino D, Williamson E, Davis TME, Laakso M,Kesaniemi YA, Zhang J, Sy RW, Lehto S, Mann S, Keech AC (inc Davoren P) (2010) Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. European Heart Journal. 31,92-98.
• Rajamani K, Colman PG, Ping L, Best JD, Voysey M, D’Emden MC, Laakso M, Baker JR, Keech AC, on behalf of the FIELD study investigators (inc Davoren P) (2009) Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 373, 1780-1788.
• Burgess DC, Hunt D, Li L, Zannino D, Williamson E, Davis TME, Laakso M, Kesaniemi YA, Zhang J, Sy RW, Lehto S, Mann S, Keech AC (inc Davoren P) (2009) Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. European Heart Journal.  1-8.
• Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen M-R, Ehnholm C, Keech A, on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (inc Davoren P) (2009) Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome. Diebetes Care. 32, 493-498.
• de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil D, Pillai A, Cooper M, Grobbee DE, Hackett M, Hamet P, Heller SR, Lisheng L, MacMahon S, Mancia G, Neal B, Pan CY, Patel A, Poulter N, Travert F, Woodward M and for the ADVANCE Collaborative group (inc Davoren P) (2009) Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 52, 2328-2336.
• Davoren P (2008) Modern management of thyroid replacement therapy. Australian Prescriber, Australia. 31:156-161.
• The ADVANCE Collaborative Group (inc Davoren P) (2008) Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine, United States of America. 358(24):2560-2572.
• Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK, for the DIRECT Programme Study Group (inc Davoren P) (2008) Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet, United Kingdom. 372:1394–1402.
• Holley AD, Green S, and Davoren P. (2007) Extreme hypernatraemia: a case report and brif review. Critical Care and Resuscitation. 9:55-58.
• William M Hague, Peter M Davoren, H David McIntyre, Ross Norris, Xiao Xiaonian, and Bruce Charles. (2003) Metformin crosses the placenta: a modulator for fetal insulin resistance? British Medical Journal. 47(7420): 880-881.
• Hague WM, Davoren PM, Oliver J, and Rowan J. (2003) Contraindications to use of metformin. Metformin may be useful in gestational diabetes.  British Medical Journal; 326:4-5.
• Fredericks B, Entsch G, Lepre F, Nolan G,  and Davoren P. (2002) Pregnancy ameliorates symptoms of insulinoma: a case report. Australia and New Zealand Journal of Obstsetrics and Gynaecology; 42:564-565.
• Hannan F and Davoren P. (2001) Use of nicotinic acid in the management of recurrent severe hypoglycaemia in diabetes mellitus. Diabetes Care. 24(7):1301.
• Davoren PM, Kelly WF, Gries A, Hubinger A, Whatley-Smith C, and Alberti KGMM. (1998) Long-term effects of a sustained -release preparation of acipimox on dyslipidaemia and glucose metabolism in non-insulin dependent diabetes mellitus. Metabolism; 47:250-256.
• Davoren PM, Motala A, and Alberti KGMM. (1995) The effect of acipimox on glucose disposal in non-insulin dependent diabetes is dependent on the lowering of non-esterified fatty acid levels. Diabetes, Nutrition & Metabolism. 8(2):99-104.
• Davoren PM and Alberti KGMM. (1995) The effect of 24 hour suppression of plasma non-esterified fatty acid levels on glucose and lipid metabolism in non-insulin dependent diabetes mellitus. Diabetes, Nutrition & Metabolism. 8:17-23.
• Davoren P and Mainstone K. (1993) Norfloxacin induced hepatitis. Medical Journal of Australia; 158:423-426.
• Davoren PM and Epstein MT. (1992) Insulinoma complicating tuberous sclerosis. J Neurol Neurosurg Psych;55:1209.
• Puvaneswary M and Davoren P. (1991) Phaeochromocytoma of the bladder: Ultrasound appearance. J Clin Ultrasound; 19:111-115.
• Davoren PM and Bowen K. (1991) Precipitating factors in diabetic ketoacidosis. Medical Journal of Australia; 154:855-856.
• Alberti KGMM, Davoren P, Fulcher G, and Walker M. (1990) Nicotinic acid in NIDDM. JAMA; 264:2994-2995.
• Davoren PM and Bowen K. (1990) Ten years of diabetic ketoacidosis. Medical Journal of Australia; 152:327-328.
• Hall C and Davoren P. (1988) An assessment of the quality of ward based blood glucose measurements. Clin Biochem Revs; 9:107.

Non-refereed conference papers

• Scott KA and Davoren PM. (2008) Low Days in Paradise - Presentations with Hypoglycaemia to the Gold Coast Hospital. Australian Diabetes Society, Annual Scientific Meeting, Melbourne.
• Davoren PM. (2001) Oral hypoglycaemic agents in pregnancy. Australasian Diabetes in Pregnancy Society, Annual Scientific Meeting, Brisbane.
• Hague Bill, Davoren Peter, Morton Mark, Jefferies Bill, Oliver John, and Hiller Janet. (2001) Metformin versus insulin in gestational diabetes: a randomised clinical trial. A pilot study of 30 women. Australasian Diabetes in Pregnancy Society, Annual Scientific Meeting, Gold Coast.
• Davoren PM. (2000) A prospective audit of pregnancy outcomes in type II diabetes mellitus. Australasian Diabetes in Pregnancy Society, Annual Scientific Meeting, Brisbane.
• Davoren P, Ludlow J, and Flynn M. (1999) HELLP syndrome at 22 weeks associated with an anti-cardiolipin antibody and activated protein C resistance. Obstetric Medicine Group of Australia Annual Scientific Meeting, Melbourne.
• Davoren PM, Elliot H, Irvine D, and Pearson J. (1998) Effects of a diabetes centre on hospital utilisation Australian Diabetes Society, Annual Scientific Meeting, Perth.
• Davoren PM and Alberti KGMM. (1994) Effects of 24 hour suppression of plasma non-esterified fatty acids on carbohydrate and lipid metabolism in non-insulin dependent diabetes mellitus. Australian Diabetes Society, Annual Scientific Meeting, Brisbane.
• Davoren PM and Epstein MT. (1994) Subacute (deQuervain's) Thyroiditis: Diagnosis, Treatment and Follow-up in 81 Consecutive Cases. Endocrine Society of Australia Annual Scientific Meeting, Brisbane.
• Davoren PM and Alberti KGMM. (1992) 24 hour suppression of non-esterified fatty acids in Type 2 diabetic patients can lower fasting blood glucose. British Diabetic Association, Spring Meeting, Harrogate.